Sign In
Buy BIIB
$207.94
+1.66 (+0.80%)
At Close: Aug 07, 2026
These Alzheimer's drugs were supposed to revolutionize the way we fight the disease. The reality is more complicated.
09:00am, Saturday, 18'th Apr 2026
A scientific report has raised questions about how much Leqimbi and Kisunla — the “breakthrough” Alzheimer's drugs that have hit the market in the last few years — really help slow the disease
Should Value Investors Buy Biogen (BIIB) Stock?
10:41am, Friday, 17'th Apr 2026
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
3 Stocks With Upgraded Broker Ratings As Markets Hit All-Time High
09:06am, Thursday, 16'th Apr 2026
Broker upgrades focus on BIIB, TEL and ZTO as the S&P 500 and Nasdaq close at record highs on hopes U.S.-Iran peace holds.
This Healthcare Stock Has Made Long-Term Investors Rich -- Can It Keep Doing It?
05:30am, Thursday, 16'th Apr 2026
Biogen's quarterly updates haven't been impressive of late. It has made regulatory progress, but that won't be enough to boost top-line growth this year.
BIIB or TECH: Which Is the Better Value Stock Right Now?
12:40pm, Wednesday, 15'th Apr 2026
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Biogen Inc. (BIIB) and Techne (TECH). But which of these two stocks is more attractive t
Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term
10:41am, Tuesday, 14'th Apr 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Biogen (BIIB) Could Beat Earnings Estimates Again
01:11pm, Tuesday, 07'th Apr 2026
Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
BOSTON--(BUSINESS WIRE)--Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug discovery technologies, today announced a colla
Why Biogen Stock Got Mashed on Monday
07:10pm, Monday, 06'th Apr 2026
Management aims to book a $34 million charge in the quarter. This is due to loftier anticipated spend on items such as milestone payments and research and development activities.
Pharma, Biotech Giants Ramp Up M&A in Q1 to Boost Pipelines
04:11pm, Monday, 06'th Apr 2026
Eli Lilly and peers like Novartis fuel a 2026 pharma M&A surge, striking billion-dollar deals to expand pipelines, tap AI innovation, and counter patent pressures.
15,051 Shares in Biogen Inc. $BIIB Bought by Element Squared LLC
05:04am, Saturday, 04'th Apr 2026
Element Squared LLC bought a new stake in shares of Biogen Inc. (NASDAQ: BIIB) in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm b
Biogen to Acquire Apellis for $5.6B to Strengthen Immunology Portfolio
11:11am, Wednesday, 01'st Apr 2026
BIIB's $5.6B offer to acquire APLS is set to add two key immunology drugs, boosting near-term revenues and strengthening its push into high-growth rare disease markets.
Burns Matteson Capital Management LLC Makes New Investment in Biogen Inc. $BIIB
05:12am, Wednesday, 01'st Apr 2026
Burns Matteson Capital Management LLC bought a new position in Biogen Inc. (NASDAQ: BIIB) during the fourth quarter, according to its most recent 13F filing with the SEC. The fund bought 3,919 shares
Econ Financial Services Corp Acquires New Position in Biogen Inc. $BIIB
04:18am, Wednesday, 01'st Apr 2026
Econ Financial Services Corp acquired a new stake in shares of Biogen Inc. (NASDAQ: BIIB) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. Th
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of A
